Video

Dr. Kirsh Discusses the Future of Treating Prostate Cancer

Author(s):

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

Localized prostate cancer continues to be treated using robotic surgery and radiation therapy, but advancements have recently been made in treatment for advanced prostate cancer.

Several agents have been approved since 2010 for advanced prostate cancer, including immunotherapy, targeting agents, and hormonal therapy. Additional agents are also anticipated to be approved soon, Kirsh adds.

In the future, Kirsh says that he sees urologists being increasingly involved in advanced prostate cancer. Urologists in LUGPA have the wherewithal and infrastructure to put together pathways and algorithms for prostate cancer treatments, Kirsh says.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD